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Abstract
Background: An association between Henoch-Schonlein purpura (HSP) and seropositivity for
Bartonella henselae (BH) has been described. The objective of this study was to see if such an
association exists in northern Alberta.
Methods: Immunofluorescent antibody testing utilizing an antigen prepared from B. henselae was
undertaken on sera from six children with current HSP, 22 children with remote HSP, and 28
controls that were matched for age. Blood from the six children with current HSP was analysed by
polymerase chain reaction (PCR) assay with primers derived from the citrate synthase (gltA) gene
for the detection of Bartonella DNA.
Results: The seropositivity rate for BH was 61% in cases versus 21% in controls (p < 0.03). The
PCR assay was negative in all six current cases.
Conclusion: There is an increased seropositivity rate for BH in children with HSP. However, it is
not clear if infection with B. henselae or a related Bartonella species can result in HSP, or if the
increased seropositivity is from non-specific or cross-reacting antibodies.
Background
Henoch Schonlein purpura (HSP) is an idiopathic form of
vasculitis, which manifests as a characteristic painless pal-
pable purpuric rash most pronounced on the buttocks
and the extensor surfaces of the lower extremities. The vas-
culitis can also involve the bowel, resulting in abdominal
pain. In severe cases, there can be melena, malabsorption,
pancreatitis or intussussception [1]. Joint involvement
occurs in the majority of cases. Renal involvement occurs
in about half of cases, and usually results in a reversible,
asymptomatic IgA-mediated nephritis, but about 1% of
patients progress to chronic renal failure [1]. Impressive
testicular swelling can occur. About 10–20% of patients
have recurrences of HSP – typically within a few weeks of
the disease appearing to resolve. Evidence of recent infec-
tion with group A streptococcus, Epstein-Barr virus (EBV),
varicella, parvovirus B19, Campylobacter, or Mycoplasma
have all been found in patients with HSP [2,3], but these
organisms do not appear to be etiologic agents.
Bartonella henselae is a fastidious gram-negative organism,
and is the etiologic agent for cat-scratch disease (CSD) [4].
Less commonly, infection with this organism results in
encephalitis, splenic or hepatic abscesses, or osteomyelitis
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[4]. The organism is presumed to be carried by fleas,
which then transmit it to cats, resulting in feline bactere-
mia. A cat bite or scratch then transmits the organism to
humans. A 2002 study from Florida demonstrated that
67% of patients with a recent diagnosis of HSP had sero-
logic evidence of infection with B. henselae (versus 14% of
a control group) [5]. It is uncertain if this means that B.
henselae causes HSP or if there is a non-etiologic associa-
tion between HSP and B. henselae.
The objective of this study was to determine if children in
northern Alberta with a current or remote diagnosis of
HSP have evidence of infection with B. henselae or a
related Bartonella species using both serology and nucleic
acid amplification.
Methods
Study population
This study was approved by the Health Ethics Review
Board of the University of Alberta. Pediatricians were
asked to notify us of children with a current or remote
diagnosis of HSP, and health records from the Stollery
Children's Hospital for 1997–2001 were searched to iden-
tify children with this diagnosis. After informed consent
was obtained, data were collected from the parents, the
patient, and the medical record on the symptoms the
child had at the time of diagnosis, the number of recur-
rences that had occurred to date, the level of exposure to
cats, and the results of any biopsies that were done. The
diagnosis of HSP was based on either i) the presence of a
classic rash with palpable purpuric lesions mainly on
lower limbs and buttocks, or ii) an atypical rash and either
abdominal pain, joint pain, lower gastrointestinal bleed-
ing, or laboratory evidence of nephritis. Patients were con-
sidered to have current HSP if onset of initial or recurrent
symptoms was less than 42 days prior to enrollment,
recent HSP if symptoms started 42 or more days prior to
enrollment but had not yet resolved, and remote HSP if
symptoms started 42 or more days prior to enrollment
and had resolved.
Paired sera were collected for B. henselae serology from test
subjects, with the convalescent sera being collected
approximately two weeks after the acute sera. Blood was
drawn for amplification of Bartonella-specific genomic
sequences by PCR assay from patients that were consid-
ered to have current HSP. Bartonella henselae serology was
also run on controls that had been matched for age (< 3
yr, 4–7 yr, 8–12 yr, or > 12 yr). Control sera were origi-
nally collected for other diagnostic purposes, and no clin-
ical information was available on these children. The
technicians were blinded as to the source of the specimens
(cases versus controls) and all specimens were run in a
single batch.
Sample size
The assumption was made that if B. henselae infection
were the sole causative organism of HSP, patients with a
current or remote diagnosis of HSP would be sero-positive
half the time, as waning antibody titers occur [6]. Assum-
ing that the seropositivity rate in the control group could
be as high as 15%, and that the diagnosis of HSP is accu-
rate, enrolling 20 patients would yield the power to dem-
onstrate that over half of cases are seropositive at a
confidence interval of 95%.
Serology
Analysis of sera for immunoglobulin (Ig) G antibodies to
B. henselae antigen was performed using an indirect
immunofluorescence assay (IFA) method with positive
and negative controls. A suspension of B. henselae (ATCC
49882) in 0.1% formal saline was prepared with bacteria
grown in-house on brain heart infusion agar supple-
mented with 5% sheep blood. The suspension was spot-
ted onto 12-well slides (#ER-202W, Erie Scientific, USA)
and air-dried for 1 hour. Slides were fixed in cold acetone
for 15 minutes, air-dried, and stored at -80 degrees Cel-
sius. For initial screening, sera from controls and test sub-
jects were diluted 1:32 in FTA Hemagglutination Buffer
(#211248, Becton Dickinson, USA). A 1:32 dilution of
goat anti-human IgG (whole molecule) FITC conjugated
antiserum was used to detect IgG antibodies. Sera reactive
at 1:32 were serially titrated two-fold to endpoint. A titer
of 1:64 or higher was interpreted as evidence for infection
at an undetermined time [6]. A titer of 1:256 or higher was
interpreted as evidence for recent infection.
Polymerase chain reaction
DNA was extracted from six blood clots using a QIAamp
DNA Mini Kit (Qiagen, Chatsworth, CA). Polymerase
chain reaction amplification to detect Bartonella-specific
sequences of the citrate synthase gene (gltA) [7] was
attempted and found to be negative. Simultaneous ampli-
fication with porphobilinogen deaminase gene primers
[8] verified that the extracted DNA was of sufficient qual-
ity for amplification.
Statistics
The proportion of seropositivity to B. henselae was com-
pared in the cases and controls using a chi-square test. A
comparison was done of seropositivity in current cases
versus remote cases, and in cases with initial onset of
symptoms ≤  12 months before the serology was drawn,
versus those who had onset of symptoms > 12 months
earlier. A p value of <0.05 was considered to be
significant.BMC Infectious Diseases 2005, 5:21 http://www.biomedcentral.com/1471-2334/5/21
Page 3 of 6
(page number not for citation purposes)
Results
Serology
There were 28 patients (21 males, 7 females) enrolled in
the study. In addition to meeting the clinical criteria for
HSP, two of these patients had HSP nephritis on renal
biopsy, and two others had leukocytoclastic vasculitis on
skin biopsy. Six patients had current HSP (five were initial
episodes, and one was a recurrence), none had recent
HSP, and 22 had remote disease. Seventeen of the 28 cases
had contact with cats (nine had contact but no bite or
scratch, five had a bite or scratch from an adult cat, and
three others had a bite or scratch from a kitten). Results of
serology are shown in Table 1. Sixty-one percent of cases
were seroreactive to B. henselae antigen versus 21% of con-
trols (p < 0.003). Paired sera were drawn 17 and 18 days
apart from two patients with current HSP, and had static
titers of 1:32 and 1:128, respectively. Figure 1 shows that
B. henselae titers did not appear to be related to the time
that had elapsed since the diagnosis of HSP and Table 2
shows that seropositivity did not seem to be related to the
season of the year in which the initial episode of HSP
occurred.
Polymerase chain reaction
From each of the six patients diagnosed with current HSP,
a single blood sample was collected on one of the follow-
ing days post onset of symptoms: 7, 18, 19, 20, 24 and 34.
All blood samples were negative by PCR assay for Bar-
tonella-specific sequences of the citrate synthase gene.
Discussion
A possible association between HSP and B. henselae infec-
tion has been noted in one previous study, with an
increased seroprevalence in children with recent onset of
HSP [5]. In this confirmatory study, there was a signifi-
cantly increased seroreactivity rate to B. henselae antigen in
28 children with a current or remote history of HSP than
in controls (p < 0.03). This is the first study to use PCR to
attempt to identify B. henselae in children with HSP, but
the organism was not detected in any of the six cases
tested. In the absence of demonstration of genomic
sequences specific to B. henselae, it is not clear if B. henselae
causes HSP. Many studies have demonstrated that sero-
logical differentiation between B. henselae and B. quintana
infections is impossible, with a cross-reactivity rate
between these species of up to 95% [6]. It is possible that
the antibodies to B. henselae in HSP patients observed here
are actually cross-reactive to B. quintana or to other bacte-
ria, or are a non-specific reaction to inflammation.
If B. henselae or a related Bartonella species is the sole caus-
ative agent of HSP, one might expect an even higher sero-
prevalence than the 61% in this study, and 67% in the
previous study [5]. Perhaps HSP is a "final common path-
way" of infection with multiple organisms including Bar-
tonella. Another explanation would be that for the patients
with current HSP, serology was run too early in the course
of their disease. A study of CSD found that titers peaked
between 2 and 16 weeks after onset of symptoms [9].
Serology was drawn 7 to 39 days after the onset of symp-
toms of HSP in the six patients with current HSP in this
study, and mainly within 28 days in the previous study
[5]. Obtaining more follow-up titers in patients with HSP
might increase the seropositivity rate or demonstrate a rise
in titers. Measuring IgM titers to B. henselae in patients
with acute HSP could also be useful, but potential prob-
lems include the lack of sensitivity of the IgM assay, and
potential cross-reactivity with IgM to EBV [6].
Another possibility is that the clinical manifestations of
HSP constitute an immunologic reaction to an infection
that has resolved, such that the titers are already waning
when the clinical features of HSP become evident. There-
fore, it is possible that some seronegative patients with
remote HSP had seroreverted by the time serology was
drawn. In the initial study of B. henselae serology in CSD,
a rapid decline in titers as measured by IFA was noted [6].
A recent study that used an enzyme immunoassay found
only 25% of patients maintained IgG to B. henselae for
more than 12 months [10]. However, in the current study,
there was no apparent relationship between the time since
diagnosis of HSP and the B. henselae titers. Other reasons
for false-negative serologic results could be that there are
differences in serologic response to different strains of B.
henselae  [6], or that the clinical diagnosis of HSP was
incorrect in some cases.
Table 1: Results of serology for B. henselae in patients with Henoch-Schonlein purpura, and in a control group
n Titer < 1:64 Titer 1:64 – 1: 128 Titer ≥  1: 256 Total seropositives
Current HSP 6 3 (50%) 2 (33%) 1 (17%) 3 (50%)
Remote HSP 22 8 (36%) 10 (45%) 4 (18%) 14 (63%)
HSP ≤  12 months earlier 11 6 (54%) 2 (18%) 3 (27%) 5 (45%)
HSP > 12 months earlier 17 5 (29%) 10 (59%) 2 (12%) 12 (71%)
All HSP 28 11 (39%) 12 (43%) 5 (18%) 17 (61%)
Controls 28 22 (79%) 6 (21%) 0 6 (21%)BMC Infectious Diseases 2005, 5:21 http://www.biomedcentral.com/1471-2334/5/21
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The B. henselae seroprevalence rate in controls of 21%
and 14% in the current study and the Florida study [5]
respectively are higher than in a summary of North Amer-
ican studies where the rate ranged from 2% [11] to 6% [6].
However, the seroprevalence was 37% in adult blood
donors and 18% in children with respiratory illnesses in a
study done in British Columbia, Canada [12]. It is well
recognized that interpretation of the IFA is subjective, and
it is probably not valid to compare titers obtained in dif-
ferent laboratories. Because there have been no previous
seroprevalence studies in Alberta, it is not clear if our sero-
prevalence rate is higher than predicted or if the specificity
of the IFA is low. Evidence for the latter is that during the
finalization of this manuscript, case and control speci-
mens after being stored for 2 years were re-analyzed by an
in-house IFA assay in a different laboratory, and all had
titres of <1:50. However, a previous study demonstrated
that in-house assay to be less sensitive than a commercial
Relationship between results of serology for B. henselae and time since onset of Henoch-Schonlein purpura Figure 1
Relationship between results of serology for B. henselae and time since onset of Henoch-Schonlein purpura
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Table 2: Seasonality of seropositivity for Bartonella henselae in 
patients with Henoch-Schonlein purpura
Month of initial onset of Henoch-
Schonlein purpura
Seropositives/Total number 
tested
January-March 3/8
April-June 1/1
July-September 6/8
October-December 7/11BMC Infectious Diseases 2005, 5:21 http://www.biomedcentral.com/1471-2334/5/21
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one [13]. A lack of specificity of our IFA would not
account for the higher seroprevalence rate in cases than in
controls.
Bartonella was not detected by PCR in the blood of six
acute cases of HSP in the current study, but it is possible
that the PCR assay that was used is not sufficiently sensi-
tive, or it may have detected the organisms if done earlier
in the course of HSP. In a study of cat-scratch disease, the
PCR was positive on the lymph nodes in 10/21 cases, with
9/10 specimens obtained in the first 6 weeks of illness
being positive but only 1/11 obtained after 6 weeks of ill-
ness being positive [9]. Another explanation for the failure
to detect Bartonella in the blood could be that the organ-
ism is present in the liver, spleen, or lymph nodes in HSP
rather than in the blood. If the clinical manifestations of
HSP constitute an immunologic reaction to an infection
that has resolved, it may be too late to detect the organism
by PCR by the time the diagnosis of HSP is evident.
Biopsy of the rash of HSP shows leukoclastic vasculitis.
This is a hypersensitivity reaction that can be caused by a
wide variety of infections, drugs, insect bites, cold expo-
sure, and malignancies [14]. Although leukoclastic vascu-
litis has been described in two cases of CSD [5,14], one
might expect many more cases if CSD and HSP are caused
by the same organism. If B. henselae is the cause of HSP, it
is a bit surprising that 39 % of our cases had no history of
contact with cats. However, in a previous study of serolog-
ically proven CSD, only 57% of patients could recall
contact with cats [9]. It is possible that humans can
acquire infection directly from fleas [4]. In addition, there
is some evidence that dogs can transmit B. henselae [15].
In summary, patients with a current or remote diagnosis
of HSP have increased seropositivity to B. henselae. How-
ever, no association was found between the antibody titre
and the time since the onset of HSP, and blood samples
in six patients with acute HSP were negative by PCR assay
for Bartonella-specific sequences. To prove if B. henselae is
related to HSP, future studies should perform more exten-
sive serologic follow-up, confirm serologic results with a
commercial assay, and perform PCR and cultures on
blood and all available tissues as early in the course of the
disease as possible. Furthermore, B. henselae serology
should be done in children with other inflammatory con-
ditions to determine if the seroreactivity is a non-specific
inflammatory response.
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